Currently out of the existing stock ratings of Adam Walsh, 79 are a BUY (87.78%), 10 are a HOLD (11.11%), 1 are a SELL (1.11%).

Adam Walsh

Work Performance Price Targets & Ratings Chart

Analyst Adam Walsh, currently employed at ROTH MKM, carries an average stock price target met ratio of 63.73% that have a potential upside of 46.24% achieved within 295 days. Previously, Adam Walsh worked at STIFEL, CANACCORD.

Adam Walsh’s has documented 173 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EQ, Equillium at 02-Jun-2026.

Wall Street Analyst Adam Walsh

Analyst best performing recommendations are on EQ (EQUILLIUM).
The best stock recommendation documented was for EQ (EQUILLIUM) at 7/10/2020. The price target of $10 was fulfilled within 3 days with a profit of $6.81 (213.48%) receiving and performance score of 711.6.

Average potential price target upside

of $27.06 (19.86%) on VRTX (VERTEX PHARMACEUTICALS).
of $25.02 (24.78%) on ASND (ASCENDIS PHARMA AS).
of $19.71 (37.01%) on RARE (ULTRAGENYX).

CNCE Concert Pharmaceuticals CORT Corcept Therapeutics INSM Insmed DRRX Durect RARE Ultragenyx ALDX Aldeyra The PHAS PhaseBio Pharmaceuticals VRTX Vertex Pharmaceuticals GLPG Galapagos NV ADR RETA Reata Pharmaceuticals ASND Ascendis Pharma AS FGEN FibroGen GLMD Galmed Pharmaceuticals Ltd PTGX Protagonist Therapeutics SAGE Sage Therapeutic VRNA Verona Pharma PLC ADR CNC Centene Corp EQ Equillium

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Stephen Kim (EVERCORE)